How Oregon is tackling high drug costs.
The Oregon Division of Financial Regulation published a list of the top 25 most-expensive prescription drugs in Oregon this week.
These are the drugs that “contribute the most to annual spending by health insurance companies,” according to OregonLive.com
According to Oregon.gov, Oregon’s Prescription Drug Price Transparency Program requires health insurance companies to report on prescription drugs in Oregon. Health insurance companies reported the 25 most prescribed drugs, the 25 most costly prescription drugs, and the 25 prescription drugs which caused the biggest increases in yearly health plan spending in 2018.
Related: Drug Prices, Shortages Remain Problem
The five costliest drugs for healthcare insurance companies are:
“The cost of these newer therapies have garnered quite a bit of attention over the past several years. These drugs were approved on the premise that they provide clinical benefit for patients with serious and chronic conditions and work best when used appropriately and consistently,” says Jerry Buller, chief pharmacy officer at Trellis Rx, a health system specialty pharmacy service partner.
The high-touch specialty pharmacy service model employed by Legacy Health in Portland is an example of a health system initiative to improve adherence to these medications, which can enhance clinical outcomes and prevent disease progression (e.g., stop progression of HCV to liver cancer) or unnecessary medical events (e.g., surgery), according to Buller.
“The embedded specialty pharmacy model also serves to elevate the role of pharmacy on care teams to ensure these high-cost medications are being used appropriately and effectively,” he says.
Conversations With Perry and Friends
April 14th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. His guest this episode is John Baackes, the former CEO of L.A. Care Health Plan.
Listen
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
Phase 3 Trial of Vertex’s Islet Cell Therapy for Type 1 Diabetes Under Way
April 23rd 2025Zimislecel is an allogeneic stem cell-derived islet cell therapy that could eliminate the need for insulin in those who have type 1 diabetes. Regulatory submissions are expected in 2026, and if approved, would be the second cell therapy for type 1 diabetes.
Read More